Merus (NASDAQ:MRUS - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Merus to post earnings of ($0.89) per share and revenue of $10.57 million for the quarter.
Merus Stock Down 0.5 %
Shares of NASDAQ:MRUS traded down $0.26 during trading on Friday, reaching $47.37. The stock had a trading volume of 613,450 shares, compared to its average volume of 602,904. The business has a fifty day moving average price of $41.63 and a 200-day moving average price of $46.97. The stock has a market cap of $3.24 billion, a P/E ratio of -11.99 and a beta of 1.11. Merus has a fifty-two week low of $37.77 and a fifty-two week high of $61.61.
Wall Street Analysts Forecast Growth
MRUS has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $85.00 target price on shares of Merus in a report on Monday, December 2nd. The Goldman Sachs Group initiated coverage on shares of Merus in a report on Thursday, November 21st. They issued a "buy" rating and a $73.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $85.00 target price on shares of Merus in a report on Monday, December 9th. Piper Sandler initiated coverage on shares of Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price for the company. Finally, Guggenheim restated a "buy" rating on shares of Merus in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $85.92.
Get Our Latest Report on MRUS
About Merus
(
Get Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
